ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting

10 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

05 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)

01 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference

21 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results

21 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results

03 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers 

11 Oct 2022 07:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

05 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million

12 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference

02 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results

03 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

28 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

08 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

15 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology

02 Jun 2022 15:10:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences

26 May 2022 07:00:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2022 Financial Results

04 May 2022 15:05:03 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

02 May 2022 15:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

05 Apr 2022 15:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

09 Mar 2022 06:00:01 By Nasdaq GlobeNewswire